BioWorld Asia

Oct. 30, 2002

Biovitrum Enters Obesity Deal With Glaxo Worth Up To $150M

Biovitrum AB entered its first major commercial alliance, a deal potentially worth up to US$150 million with GlaxoSmithKline plc to develop and commercialize its collection of proprietary 5-hydroxytryptamine 2C receptor agonists for the treatment of obesity and other indications. (BioWorld International) Read More

Genome Canada First Partner Of Netherlands Genomics Initiative

Tubulin-Folding Defect Found To Cause Retardation Syndrome

British Biotech Ends Merger Discussions With MorphoSys

Other News To Note

Correction

Sireen Raises EUR5M Privately To Advance Discovery Program

Astex Solves Crystal Structure Of Human Cytochrome P450 3A4

ExonHit Initiates Clinical Trial Of Lead Compound For ALS

EcoBiotics Raising A$3M To Further Biodiscovery Program

Genome Express Unveils New Gene Discovery Technology

Genset Delists From Nasdaq, Closes Paris Headquarters

PowderJect Receives Preliminary Offers, Won't Confirm Chiron Bid

IDM Enters Research Agreement With Nemod On Immunotherapies

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...